Agenus' Potential Colorectal Cancer Combination Shows 21.2-Month Survival
MT Newswires Live
Jul 06
Agenus (AGEN) three-year, 123-patient phase 1b study of its drug botensilimab plus balstilimab in patients with refractory microsatellite-stable metastatic colorectal cancer without active liver metastases showed 21.2-month median overall survival, a 33% three-year overall survival, and a survival curve plateau beyond two years.
A safety follow-up showed no new safety signals or treatment-related deaths, the company said.
The drug combination showed "clinically meaningful long-term survival" among heavily pretreated patients with few other treatment options after progression on standard therapies, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.